SCHEMBL29526607

SCHEMBL29526607

CCc1cc(Oc2c(Cl)cc(N3NC=CN=C3N)cc2Cl)cn(C(C)C)c1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29526858 0.84 NPBWR1 (0.32) —
SCHEMBL24407980 0.76 THRB (0.55) —
SCHEMBL29527217 0.73 NPBWR1 (0.37) —
SCHEMBL29527157 0.70 THRA (0.33) —
SCHEMBL29527914 0.70 — —
SCHEMBL24407944 0.70 THRB (0.52) —
SCHEMBL29527135 0.70 THRA (0.31) —
SCHEMBL29526860 0.67 NPBWR1 (0.36) —
SCHEMBL29527397 0.66 NPBWR1 (0.34) —
SCHEMBL24407941 0.65 THRB (0.58) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4240730-A1 2-PYRIDONES AS THYROID HORMONE RECEPTOR MODULATORS Aligos Therapeutics, Inc. (US) 2023-09-13 — — EP disclosed
WO-2022099044-A1 2-PYRIDONES AS THYROID HORMONE RECEPTOR MODULATORS ALIGOS THERAPEUTICS, INC. (US) 2022-05-12 — — WO disclosed
Send feedback